Stephen Anderson

Dr. Stephen Anderson

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2019 in Immunity
Verified
Journal Article
Closed access
AFAdriana Forero
Adriana Forero
SOSnehal Ozarkar
Snehal Ozarkar
HLHongchuan Li
Hongchuan Li
CLChia Heng Lee
Chia Heng Lee
EHEmily A. Hemann
Emily A. Hemann
RSRam Savan
Ram Savan

10 March 2019 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
VSVeena Somasundaram
Veena Somasundaram
DBDebashree Basudhar
Debashree Basudhar
GBGaurav Bharadwaj
Gaurav Bharadwaj
JNJae Hong No
Jae Hong No
LRLisa A. Ridnour
Lisa A. Ridnour
DWDavid A. Wink
David A. Wink
Cancer is a complex disease, which not only involves the tumor but its microenvironment comprising different immune cells as well. Nitric oxide (NO) plays specific roles within tumor cells and the microenvironment and determines the rate of cancer progression, therapy efficacy, and patient prognosis. Recent Advances: Key understanding of the processes leading to dysregulated NO flux within the tumor microenvironment over the past decade has provided better understanding of the dichotomous role of NO in cancer and its importance in shaping the immune landscape. It is becoming increasingly evident that nitric oxide synthase 2 (NOS2)-mediated NO/reactive nitrogen oxide species (RNS) are heavily involved in cancer progression and metastasis in different types of tumor. More recent studies have found that NO from NOS2+ macrophages is required for cancer immunotherapy to be effective. NO/RNS, unlike other molecules, are unique in their ability to target a plethora of oncogenic pathways during cancer progression. In this review, we subcategorize the different levels of NO produced by cells and shed light on the context-dependent temporal effects on cancer signaling and metabolic shift in the tumor microenvironment. Understanding the source of NO and its spaciotemporal profile within the tumor microenvironment could help improve efficacy of cancer immunotherapies by improving tumor infiltration of immune cells for better tumor clearance.

1 June 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
SJSean Judge
Sean Judge
CDCordelia Dunai
Cordelia Dunai
EAEthan G. Aguilar
Ethan G. Aguilar
SVSarah C. Vick
Sarah C. Vick
ISIan R. Sturgill
Ian R. Sturgill
William J. MurphyWilliam J. Murphy
William J. Murphy
PD-1 expression is a hallmark of both early antigen-specific T cell activation and later chronic stimulation, suggesting key roles in both naive T cell priming and memory T cell responses. Although significant similarities exist between T cells and NK cells, there are critical differences in their biology and functions reflecting their respective adaptive and innate immune effector functions. Expression of PD-1 on NK cells is controversial despite rapid incorporation into clinical cancer trials. Our objective was to stringently and comprehensively assess expression of PD-1 on both mouse and human NK cells under multiple conditions and using a variety of readouts. We evaluated NK cells from primary human tumor samples, after ex vivo culturing, and from multiple mouse tumor and viral models using flow cytometry, quantitative reverse-transcriptase PCR (qRT-PCR), and RNA-Seq for PD-1 expression. We demonstrate that, under multiple conditions, human and mouse NK cells consistently lack PD-1 expression despite the marked upregulation of other activation/regulatory markers, such as TIGIT. This was in marked contrast to T cells, which were far more prominent within all tumors and expressed PD-1. These data have important implications when attempting to discern NK from T cell effects and to determine whether PD-1 targeting can be expected to have direct effects on NK cell functions.

25 October 2012 in Blood
Verified
Journal Article
Open access
PDF file
NBNiklas Björkström
Niklas Björkström
Vivien BéziatVivien Béziat
Vivien Béziat
FCFrank Cichocki
Frank Cichocki
LLLisa L. Liu
Lisa L. Liu
JLJeffrey Levine
Jeffrey Levine
KMKarl-Johan Malmberg
Karl-Johan Malmberg
Epistatic interactions between killer cell immunoglobulin-like receptors (KIRs) and their cognate HLA class I ligands have important implications for reproductive success, antiviral immunity, susceptibility to autoimmune conditions and cancer, as well as for graft-versus-leukemia reactions in settings of allogeneic stem cell transplantation. Although CD8 T cells are known to acquire KIRs when maturing from naive to terminally differentiated cells, little information is available about the constitution of KIR repertoires on human CD8 T cells. Here, we have performed a high-resolution analysis of KIR expression on CD8 T cells. The results show that most CD8 T cells possess a restricted KIR expression pattern, often dominated by a single activating or inhibitory KIR. Furthermore, the expression of KIR, and its modulation of CD8 T-cell function, was independent of expression of self-HLA class I ligands. Finally, despite similarities in the stochastic regulation of KIRs by the bidirectional proximal promoter, the specificity of inhibitory KIRs on CD8 T cells was often distinct from that of natural killer cells in the same individual. The results provide new insight into the formation of KIR repertoires on human T cells.

12 May 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
HLHong Lou
Hong Lou
MYMeredith Yeager
Meredith Yeager
HLHongchuan Li
Hongchuan Li
JBJesus Gonzalez Bosquet
Jesus Gonzalez Bosquet
RHRichard B. Hayes
Richard B. Hayes
SCStephen J. Chanock
Stephen J. Chanock
Two recent genome-wide association studies have independently identified a prostate cancer susceptibility locus on chromosome 10q11.2. The most significant single-nucleotide polymorphism (SNP) marker reported, rs10993994, is 57 bp centromeric of the first exon of the MSMB gene, which encodes β-microseminoprotein (prostatic secretory protein 94). In this study, a fine-mapping analysis using HapMap SNPs was conducted across a ≈65-kb region (chr10: 51168330–51234020) flanking rs10993994 with 13 tag SNPs in 6,118 prostate cancer cases and 6,105 controls of European origin from the Cancer Genetic Markers of Susceptibility (CGEMS) project. rs10993994 remained the most strongly associated marker with prostate cancer risk [ P = 8.8 × 10 −18 ; heterozygous odds ratio (OR) = 1.20, 95% confidence interval (CI): 1.11–1.30; homozygous OR = 1.64, 95% CI: 1.47–1.86 for the adjusted genotype test with 2 df]. In follow-up functional analyses, the T variant of rs10993994 significantly affected expression of in vitro luciferase reporter constructs. In electrophoretic mobility shift assays, the C allele of rs10993994 preferentially binds to the CREB transcription factor. Analysis of tumor cell lines with a CC or CT genotype revealed a high level of MSMB gene expression compared with cell lines with a TT genotype. These findings were specific to the alleles of rs10993994 and were not observed for other SNPs determined by sequence analysis of the proximal promoter. Together, our mapping study and functional analyses implicate regulation of expression of MSMB as a plausible mechanism accounting for the association identified at this locus. Further investigation is warranted to determine whether rs10993994 alone or in combination with additional variants contributes to prostate cancer susceptibility.

1 July 2004 in Immunity
Verified
Journal Article
Closed access
ASAli Saleh
Ali Saleh
GDGareth E. Davies
Gareth E. Davies
VPVeronique Pascal
Veronique Pascal
PWPaul W. Wright
Paul W. Wright
DHDeborah L. Hodge
Deborah L. Hodge
SAStephen Anderson
Stephen Anderson